Last reviewed · How we verify
Subcutaneous injection of CU-20401
At a glance
| Generic name | Subcutaneous injection of CU-20401 |
|---|---|
| Also known as | cu-20401 |
| Sponsor | Cutia Therapeutics（Wuxi）Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Clinical Study of CU-20401 (PHASE2)
- A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population (PHASE1)
- A Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: